Dow Jones
32.859,03 +141,43 (+0,43%) Nasdaq
12.013,47 +87,24 (+0,73%) Nikkei 225
28.046,75 +263,82 (+0,95%) EUR/USD
1,0912 +0,0004 (+0,03%) Bitcoin EUR
25.819,37 -767,86 (-2,89%) CMC Crypto 200
615,20 -4,04 (-0,65%)
Sanofi (SAN.PA)
| Chiusura precedente | 101,00 |
| Aperto | 100,46 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 99,03 - 101,14 |
| Intervallo di 52 settimane | 76,45 - 106,66 |
| Volume | |
| Media Volume | 1.805.562 |
| Capitalizzazione | 124,16B |
| Beta (5 anni mensile) | 0,39 |
| Rapporto PE (ttm) | 15,09 |
| EPS (ttm) | 6,59 |
| Prossima data utili | 27 apr 2023 |
| Rendimento e dividendo (forward) | 3,56 (3,52%) |
| Data ex dividendo | 30 mag 2023 |
| Stima target 1A | 101,70 |
- GlobeNewswire
Press Release: Availability of the Q1 2023 Memorandum for modelling purposes
Availability of the Q1 2023 Memorandum for modelling purposes Paris, France – March 30, 2023 - Sanofi announced today that its Q1 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q1-results-2023 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various no
- GlobeNewswire
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placeboFirst and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to placebo (77 mL in FEV1) First and only biologic to demonstrate significant improvements in quality of life
- GlobeNewswire
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placeboPatients treated with Dupixent achieved rapid itch reduction as early as three weeks after start of therapy, with significant
